The Latest Breaking News from Moderna

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.

Shares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study

The decision aims to better protect the littlest kids amid an uptick in COVID-19 cases around the country. The Centers for Disease Control and Prevention is expected to sign off soon.

Biotech giant Moderna's first mRNA vaccine facility in Australia is due to open in 2024, and will produce 100 million vaccine doses per year.

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.

Kate Bingham raises concerns to committee of MPs as head of UKHSA suggests Covid could be on rise again

How scientists across Africa plan to use mRNA technology to fight diseases and tackle inequities in global health.

The US researchers have created a vaccine based on the same mRNA technology used in the Covid-19 jabs from Moderna and Pfizer.